This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Natalizumab is a monoclonal antibody that acts as an α4 integrin antagonist to prevent leukocyte trafficking into the central nervous system (1)

Natalizumab (branded and biosimilar) has a marketing authorisation as a single disease-modifying therapy in highly active relapsing-remitting multiple sclerosis for the following groups (2):

  • patients with rapidly evolving severe relapsing–remitting multiple sclerosis defined by 2 or more disabling relapses in 1 year, and 1 or more gadolinium-enhancing lesions on brain MRI or a significant increase in T2 lesion load compared with a previous MRI. This patient group is referred to as the 'RES group'
  • patients with high disease activity despite treatment with beta interferon
    • group is defined as patients who have failed to respond to a full and adequate course of a beta interferon
    • patients should have had at least 1 relapse in the previous year while on therapy, and have at least 9 T2-hyperintensive lesions in cranial MRI or at least 1 gadolinium-enhancing lesion
    • this patient group is referred to as the 'suboptimal therapy group'

NICE state (2):

  • natalizumab (branded or biosimilar) is recommended as an option for the treatment only of rapidly evolving severe relapsing - remitting multiple sclerosis (RES‑RRMS) in adults. RES‑RRMS is defined by 2 or more relapses in the previous year, and baseline MRI evidence of disease activity

Reference:

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.